Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11296050 | 0.94 | MCL1 (0.48) | NR1H3ESR1HDAC6HDAC8HDAC3 | |
| SCHEMBL11305637 | 0.89 | HDAC6 (0.57) | NR1H3ESR1HDAC6HDAC8HDAC3 | |
| SCHEMBL11299418 | 0.89 | HDAC8 (0.44) | HDAC6HDAC8HDAC3HDAC11HSD17B10 | |
| SCHEMBL11306334 | 0.81 | HDAC1 (0.45) | HDAC6HDAC8HDAC3SLC6A2SLC6A4 | |
| SCHEMBL11302583 | 0.78 | SLC6A2 (0.53) | HDAC6HDAC8HDAC3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL9785714 | 0.76 | ESR1 (0.58) | NR1H3ESR1MCL1TSHRMAPK1 | |
| SCHEMBL11300778 | 0.75 | HDAC1 (0.49) | HDAC6HDAC8HDAC3SLC6A2SLC6A4 | |
| SCHEMBL11301824 | 0.73 | KDM4E (0.39) | HDAC6HDAC8SLC6A2SLC6A4HDAC1 | |
| SCHEMBL11300763 | 0.72 | HDAC8 (0.42) | HDAC8ALOX15 | |
| SCHEMBL11298741 | 0.71 | SLC6A4 (0.45) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665706-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-27 | — | — | EP | claimed |
| US-8404738-B2 | 4-amino-N-hydroxy-benzamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | claimed |
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. | 2012-07-26 | — | — | US | claimed |
| WO-2012098132-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | claimed |
| EP-2665706-B1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| EP-2665706-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| US-8404738-B2 | 4-amino-N-hydroxy-benzamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2012098132-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HRH4, H1-4, HNMT | NR1H3 1535/4885ESR1 674/4885HDAC6 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.